Welcome to our dedicated page for Viaderma news (Ticker: VDRM), a resource for investors and traders seeking the latest updates and insights on Viaderma stock.
ViaDerma, Inc. (VDRM) is a specialty pharmaceutical company focused on transdermal drug delivery and topical antibiotic products, and its news flow reflects this focus. Company updates highlight developments around its tetracycline-based topical antibiotic, Vitastem, and Vitastem Ultra, as well as broader product pipeline initiatives in areas such as anti-aging skincare, pain management, hair-loss treatments, sexual wellness products, and CBD-based formulations.
News releases frequently cover ViaDerma’s international expansion, including shipments of its flagship topical antibiotic to Nigeria, the opening of a satellite office in Dubai, and the finalization of distribution agreements in Dubai to reach markets in the Middle East and Eastern Europe. Additional coverage includes progress on product registration in India and the start of registration processes in countries such as Kenya, Namibia, and Tanzania, along with plans for further applications across Africa, Europe, and the Middle East.
Investors and observers can also find financial and operational updates in ViaDerma’s news, such as quarterly and half-year results, changes in cash position, and commentary on profitability and liabilities. The company has issued statements about remaining fully operational, working to complete overdue financial reports, and exploring strategic options related to its public status on OTC Markets and the OTC Expert Market.
Other recurring themes in ViaDerma news include stability testing for Vitastem Ultra, licensing and regulatory milestones, staffing and organizational growth, and discussions with potential partners such as healthcare organizations and government-related entities. For anyone tracking VDRM, the news feed offers insight into the company’s product progress, geographic expansion, financial condition, and evolving regulatory and market strategy.
Summary not available.
ViaDerma, Inc. (OTC Pink: VDRM) has announced the brand name Nupelo for its upcoming minoxidil hair regrowth product. The company recently submitted an application for FDA registration, expected to be completed within weeks. Nupelo will utilize ViaDerma’s proprietary dual carrier transdermal delivery technology, aimed at effectively regrowing hair rather than just reducing hair loss. The product is set to launch for purchase online by the end of Q2 2023, with availability on various platforms including nupelo.com. CEO Dr. Chris Otiko highlighted the speed and effectiveness of the development process.
ViaDerma, Inc. (VDRM) announced plans to launch a new hair regrowth product using Minoxidil with a proprietary transdermal delivery technology. This technology enhances absorption, significantly outperforming traditional treatments. The global hair restoration market is projected to reach $13.6 billion by 2028, while the Minoxidil market is expected to grow to $1.43 billion during the same time frame. FDA registration for the product is anticipated within 90 days, aiming for market availability later this year. CEO Dr. Chris Otiko expressed excitement about entering this expanding industry.
ViaDerma, Inc. (OTC Pink: VDRM) has expanded its licensing agreement with a major wound care network to 11 states, aiming for nationwide coverage within 12 months. This expansion increases monthly royalties from $50,000 to $55,000. The company has also launched a new website, ViaDerma.com, to enhance brand recognition and customer engagement. Additionally, ViaDerma is pursuing insurance coverage for its products, Vitastem and Vitastem Ultra, which are eligible for OTC benefits. President & CEO Dr. Chris Otiko noted recovery from previous supply chain issues, with optimistic sales forecasts for 2023.
ViaDerma, Inc. (OTC Pink: VDRM) has engaged INTENT SCIENCES to enhance its online brand and marketing efforts in 2023. The partnership aims to leverage INTENT SCIENCES' expertise in digital marketing to grow demand for ViaDerma's flagship product, Vitastem Ultra, which addresses various skin ailments. With over 35 million monthly searches for related conditions, this collaboration focuses on improving search visibility and increasing revenues. ViaDerma is also pursuing several large purchase orders, signaling confidence in future growth.
ViaDerma, Inc. (OTC Pink: VDRM) announced the successful completion of internal quality control testing for its new Vitastem products, allowing the company to resume online sales. The new formulations, Vitastem and Vitastem Ultra, are FDA-registered topical antibiotics effective against various bacteria associated with skin conditions. The CEO, Dr. Chris Otiko, expressed confidence in moving forward with sales and potential purchase orders. The company plans to file its second-quarter financial report soon, resolving delays due to missing information.
ViaDerma (OTC Pink: VDRM) has announced that large-scale production of its new Vitastem products is underway and additional internal quality control testing will be conducted. The company aims to ensure optimal performance of these FDA-registered topical antibiotics, which utilize new formulations. The upgraded products, Vitastem and Vitastem Ultra, offer enhanced efficacy against harmful bacteria and provide alternatives for consumers with ingredient sensitivities. Completion of the testing is expected within four weeks, with distribution commencing shortly thereafter.
ViaDerma, Inc. (VDRM) reported a staggering 4382% revenue increase in 2021, totaling $514,007 compared to $11,468 in 2020. Gross profits surged by 4621%, rising from $10,831 to $511,335. The company also improved its asset figures, with total assets rising by 123% to $275,021. Furthermore, total liabilities decreased by over 25%, from $3,631,096 to $2,710,201. CEO Dr. Chris Otiko acknowledged the challenges posed by COVID-19 but expressed optimism for resumed production and sales of Vitastem.
ViaDerma, Inc. (OTC Pink: VDRM) announces the launch of enhanced formulas for its popular products, Vitastem and Vitastem Ultra. The original Vitastem, a strong topical antibiotic, now features a clear, non-staining formula, making it user-friendly. Vitastem Ultra, with bacitracin as its active ingredient, offers an alternative for those allergic to tetracycline or dealing with resistant bacteria. Both products are set to be available by mid-October through Amazon and other retailers. The previous versions will be phased out as the new products are introduced.
ViaDerma, Inc. (OTC Pink: VDRM) reported on August 24, 2021, a quarterly financial review revealing Convertible Notes Payable of $281,538 and a Convertible Line of Credit totaling $19,000. An internal audit disclosed that outstanding convertible debt was actually $300,358, contradicting a previous statement about settling these liabilities. Additionally, VDRM identified an unrecorded liability of $200,000. The company is preparing to receive funds from a recent Dubai transaction, which will facilitate a financial audit, a crucial step toward potential OTCQB listing.